Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101293382 Publication Model: Electronic Cited Medium: Internet ISSN: 1752-1947 (Electronic) Linking ISSN: 17521947 NLM ISO Abbreviation: J Med Case Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, [2007-
    • الموضوع:
      Immunocompromised Host*; Antiviral Agents/*therapeutic use ; Hepatitis B/*immunology ; Hepatitis B virus/*pathogenicity ; Immunosuppressive Agents/*therapeutic use ; Lymphoma, Non-Hodgkin/*immunology ; Rituximab/*therapeutic use ; Tenofovir/*therapeutic use; Contact Tracing ; Female ; Hepatitis B/transmission ; Hepatitis B Antibodies/blood ; Humans ; Lymphoma, Non-Hodgkin/drug therapy ; Middle Aged ; Treatment Outcome
    • نبذة مختصرة :
      Background: Despite the introduction of universal hepatitis B immunization programs worldwide, outbreaks of acute infection still occur in unimmunized individuals. A timely diagnosis of hepatitis B is necessary to ensure adequate clinical care and public health interventions that will reduce transmission. Yet, interpretation of hepatitis B serological markers can be complex. We present a case of hepatitis B with atypical markers, including delayed appearance of hepatitis B core antibody.
      Case Presentation: A 62-year-old white woman was identified as a sexual contact of a male individual with acute hepatitis B virus infection. She had a history of recurrent low-grade non-Hodgkin lymphoma and had recently received immunosuppressive therapy. At baseline she had a negative serology and received three double doses (40 μg) of Engerix-B vaccine (hepatitis B vaccine) with a 0-month, 1-month, and 6-month schedule. One month following the last dose, hepatitis B surface antigen was positive in the absence of hepatitis B core antibody. The only sign of infection was a slight elevation of alanine aminotransferase enzymes a few months after first sexual contacts with the male individual. Hepatitis B virus infection was later confirmed despite the absence of hepatitis B core antibody. The development of hepatitis B core antibody was finally noted more than 6 months after the first positive hepatitis B surface antigen and more than 12 months after elevation of alanine aminotransferase enzymes. Immunosuppression including rituximab treatment was the most likely explanation for this serological profile. On her last medical assessment, she had not developed HBeAg seroconversion despite lower hepatitis B virus deoxyribonucleic acid levels with tenofovir treatment.
      Conclusions: When confronted with positive hepatitis B surface antigen in the absence of hepatitis B core antibody, consideration should be given to the possibility of both acute and persistent infection particularly in the setting of immunosuppression so that appropriate clinical management and public health interventions can take place. Given the increasing use of biologicals such as anti-tumor necrosis factor therapies either alone or with other immunosuppressive agents, this phenomenon may be encountered more frequently.
    • References:
      J Hepatol. 1996 Feb;24(2):155-60. (PMID: 8907568)
      J Allergy Clin Immunol. 2011 Dec;128(6):1295-1302.e5. (PMID: 21908031)
      J Med Virol. 1994 Feb;42(2):109-14. (PMID: 8158103)
      J Clin Microbiol. 2006 Jun;44(6):2250-3. (PMID: 16757632)
      Pediatrics. 2000 Jun;105(6):E81. (PMID: 10835094)
      Med Microbiol Immunol. 2011 Feb;200(1):13-22. (PMID: 20458499)
      World J Gastroenterol. 2014 Dec 14;20(46):17360-7. (PMID: 25516647)
      MMWR Recomm Rep. 2006 Dec 8;55(RR-16):1-33; quiz CE1-4. (PMID: 17159833)
      Vaccine. 1990 Mar;8 Suppl:S15-7; discussion S21-3. (PMID: 2327151)
      Hepatology. 1989 Aug;10(2):179-85. (PMID: 2744730)
      J Hepatol. 1991 Sep;13(2):187-91. (PMID: 1744423)
      BMC Infect Dis. 2015 Jun 12;15:227. (PMID: 26062979)
      Health Rep. 2012 Mar;23(1):7-16. (PMID: 22590801)
      Hepatology. 1990 Feb;11(2):271-6. (PMID: 2307406)
      MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19. (PMID: 24352112)
      Lancet. 1982 Feb 13;1(8268):361-4. (PMID: 6120349)
    • Contributed Indexing:
      Keywords: Anti-HBc; HBsAg; Hepatitis B virus infection; Immunosuppression; Rituximab
    • الرقم المعرف:
      0 (Antiviral Agents)
      0 (Hepatitis B Antibodies)
      0 (Immunosuppressive Agents)
      4F4X42SYQ6 (Rituximab)
      99YXE507IL (Tenofovir)
    • الموضوع:
      Date Created: 20170418 Date Completed: 20170908 Latest Revision: 20181113
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC5393022
    • الرقم المعرف:
      10.1186/s13256-017-1264-9
    • الرقم المعرف:
      28412974